Drugs / OM-85-IN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06486662 | Jun 2024 → Feb 2025 | allergic asthma | OM Pharma SA | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-05-15 | OM Pharma SA | Results OM Pharma and Fraunhofer ITEM release clinical study data at American Thoracic Society conference 2025 ompharma.com ↗
The Phase 1a/b study demonstrated that OM-85 bacterial lysate administered intranasally has a good safety profile and is well-tolerated by both healthy subjects and patients with mild asthma. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-05-15 | OM Pharma SA | OM Pharma and Fraunhofer ITEM release clinical study data at American Thoracic Society conference 2025 ompharma.com ↗ |
| 2024-07-25 | OM Pharma SA | First Participant Dosed in Phase 1a/1b Clinical Trial Evaluating Safety and Tolerability of OM-85-In ompharma.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OM-85-IN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06486662 ↗ |